265313-99-3

Upstream product

• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 670749-42-5 5-acryloyl-2-[2-(4-chloro-phenylsulfanyl)-ethoxy]-3-methoxy-benzonitrile 
• 881-68-5 vanillin acetate 
• 486994-14-3 4-(acetyloxy)-3-iodo-5-methoxybenzaldehyde 
• 245469-65-2 1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]prop-2-en-1-one 
• 670749-41-4 1-[4-(2-bromo-ethoxy)-3-iodo-5-methoxy-phenyl]-propenone 
• 670749-39-0 1-(3-methoxy-4-hydroxy-5-iodophenyl)-prop-2-en-1-ol 
• 670749-40-3 1-(3-methoxy-4-hydroxy-5-iodophenyl)-prop-2-en-1-one 

Relevant academic research and scientific papers

Synthesis of (±)-trans-2-[3-methoxy-4-(4 chlorophenylthioethoxy)-5-(N-methyl-N-hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran

The synthesis of (± )-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N-hydroxyureidyl) methylphenyl]-5-(3,4,5-trimethoxyphenyl) tetrahydrofuran from commercially available vanillin acetate and 3,4,5-trimethoxy benzaldehyde is reported.

PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS

A pharmaceutical formulation is provided for the treatment of inflammatory and/or immune disorders, particularly those mediated by platelet activating factor (“PAF”) or a product of 5-lipoxygenase. The formulation, in one embodiment, is an essentially anhydrous ointment containing an active agent selected from the group consisting of 2,5-diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines, and an enhancer composition containing one or more C3-18 esters such as diethyl succinate, propylene carbonate, diisopropyl adipate and glyceryl triacetate. In another embodiment, the formulation is a cream, gel, lotion, oil, or the like, containing the: active agent in crystalline form. The invention also encompasses the novel crystalline form of the active agent, and methods for using the formulations to treat individuals with inflammatory and/or immune disorders. Also encompassed is use of isopropyl alcohol (IPA) to enhance stability of the active agent and pharmaceutical formulations.